 The phase I trial aims to determine the recommended phase II dose RP2D of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced phaeochromocytoma phaeo and paraganglioma PG by assessing the safety and tolerability of the combination treatment. 